JBIO · Jade Biosciences Inc
United States · RS rating 21 · As of 2026-10-14
| Price | 13.44 USD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 10 / 10 / 89 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 25 / 26 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -33.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +49.9% |
| Market cap (USD) | $1.2B |